Company / SG&A Expense
Ginkgo Bioworks Holdings, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$183.3M
FY2025
5-year range
$183.3M / $1.4B
FY2021-FY2025
Trend
-25.5%
vs FY2024
Sector context
#75 of 211
Health Care
What the data says
At $183M, Ginkgo Bioworks Holdings, Inc.'s sg&a expense ranks #137 of 211 in the Health Care sector. SG&A Expense has declined for 3 consecutive years, from $1.4B in FY2022 to $183M in FY2025.
Based on SEC 10-K filings.
$183M in FY2025 with a 5-year CAGR of +36.8%.
Improved from $385M to $183M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -49.6%
- 5-Year CAGR
- +36.8%
- 10-Year CAGR
- -
Sector benchmark
#137 of 211 in Health CareTop 64% of 211This company $183.3M Sector average $728.7M
▼
-74.8% below sector average
Key checks
Key Insights
- Ginkgo Bioworks Holdings, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of +36.8%, indicating consistent growth.
- In FY2025, sg&a expense decreased 25.5% year-over-year.
- Ranks #75 out of 211 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $183.3M | -25.5% |
| FY2024 | $246.2M | -36.1% |
| FY2023 | $385.0M | -73.1% |
| FY2022 | $1.4B | +65.7% |
| FY2021 | $863.0M | +2152.8% |
| FY2020 | $38.3M | +29.9% |
| FY2019 | $29.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026